Back Home About Us

CROI 2015: Levonorgestrel Contraception May Be Less Effective for Women Taking Efavirenz

African women who took efavirenz as part of a combination antiretroviral regimen were more likely to become pregnant while using the levonorgestrel implant, likely due to a drug interaction that lowers levels of the hormonal contraceptive, according to a presentation at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.

alt

Read more:

Trial of CCR5-Deleted Stem Cell Gene Therapy for HIV Gets FDA Go-Ahead

The U.S. Food and Drug Administration (FDA) has given approval to proceed with a clinical trial of a gene therapy method that cuts the gene for the CCR5 coreceptor out of stem cells, making them resistant to HIV entry, the California Institute for Regenerative Medicine (CIRM) recently announced.

alt

Read more:

CROI 2015: Stopping Co-trimoxazole During ART Raises Risk of Bacterial Illness and Malaria

Stopping trimethoprim/sulfamethoxazole (Co-trimoxazole) prophylaxis increases the risk of serious bacterial infections and malaria, even at high CD4 cell counts, among people with HIV taking antiretroviral therapy (ART) in Uganda, according to results of a randomized trial presented by Jonathan Levin of the UK Medical Research Council at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.

alt

Read more:

Valacyclovir May Reduce HIV Viral Load Even in People Without Herpes

The antiviral drug valacyclovir (Valtrex and generics), used to treat herpes simplex virus type 2 (HSV), led to a decrease in HIV viral load even among individuals who did not have genital herpes, according to a small study reported in the March 3 advance edition of Clinical Infectious Diseases.

alt

Read more:

Study Suggests HIV May Be Less Infectious than Assumed During Early Infection

The likelihood of HIV transmission during the acute phase of HIV infection may not be as high as previously estimated based on data from a retrospective cohort study in Rakai, Uganda, according to an analysis published in the March 17 edition of PLoS Medicine. If confirmed, these findings suggests that antiretroviral treatment as prevention (TasP) may be even more effective, as it would not be compromised as much by transmission occurring before partners with HIV are diagnosed and start therapy.

alt

Read more:

CROI 2015: Experimental Agents Reverse HIV Latency, Help Immune System Fight Infected Cells

Researchers at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle presented data on several experimental agents that may play a role in achieving a "functional cure" for HIV, or prolonged remission without disease progression. These include drugs that reactivate the latent HIV reservoir, interfere with expression of viral DNA, and help the immune system target HIV-infected cells.

alt

Read more:

CROI 2015: Does Emtricitabine Work Better than Lamivudine in Combination ART?

People with HIV who started an antiretroviral regimen containing emtricitabine (FTC; Emtriva) and NNRTIs were about half as likely to experience virological treatment failure as those who used the similar drug lamivudine (3TC; Epivir), according to an analysis of more than 6000 participants in the Dutch ATHENA cohort presented at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle. No significant differences between emtricitabine and lamivudine were seen with boosted protease inhibitor regimens.

alt

Read more:

Today Is National Native HIV/AIDS Awareness Day

March 20 marks the 9th annual observation of National Native HIV/AIDS Awareness Day (NNHAAD), an occasion to highlight the impact of HIV and AIDS on American Indian, Alaska Native, and Native Hawaiian communities.

alt

Read more:

CROI 2015: Researchers Discuss HIV Cure Strategies

Researchers at the recent 2015 Conference on Retroviruses and Opportunistic Infections in Seattle discussed a variety of approaches to achieve a functional cure, or prolonged remission of HIV. Most experts expect that a combination of multiple approaches will be needed.

Early Antiretroviral Treatment Reduces, but Does Not Eliminate HIV Reservoir

Experimental Agents Reverse HIV Latency, Help Immune System Fight Infected Cells

We May Need to Combine Many Approaches to Achieve a Cure for HIV

3/20/15

alt